Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2025 and 2026.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
ViroVet from Leuven, company number BE0634891328, closed financial year 2026 with a result of € -238,871 after tax. Compared with financial year 2025, the result moved from € -1.5 million to € -238,871. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ -3.6 million
▼ € 238,871 vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -238,871
▲ 84 % less loss than in 2025
Profit after tax over the fiscal year.
€ 7,128
▼ 89% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -9.6 million.
Debts at end 2026
€ 3 million
Loans from banks and other lenders, long and short.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Profit after taxes | € -2,594,575 | € -2,679,475 | € -1,462,362 | € -238,871 | ▲ € 1.2 million |
| Equity | € 816,272 | € -1,863,203 | € -3,325,565 | € -3,564,436 | ▼ € 238,871 |
| Total debts | € 1,530,245 | € 3,658,036 | € 3,602,085 | € 3,732,969 | ▲ 4% |
| Cash | € 1,559,617 | € 1,042,554 | € 67,279 | € 7,128 | ▼ 89% |
| Retained profit | € -5,193,566 | € -7,873,041 | € -9,335,403 | € -9,574,274 | ▼ € 238,871 |
| Bank debt | € 1,266,959 | € 3,000,000 | € 3,000,000 | € 3,000,000 | |
| Balance sheet total | € 2,346,517 | € 1,794,833 | € 276,520 | € 168,533 | ▼ 39% |
| Employees (FTE) | 11.3 | 10.8 | 3.8 | - |
Key figures of ViroVet, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 25 January 2028.
What happened to ViroVet?
What happened at ViroVet in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 238,871. Source: NBB ↗
- Patrik Haesen stepped down as director. NBB
- Biotech Fonds Vlaanderen NV stepped down as director. NBB
- VIVES Partners SRL stepped down as director. NBB
- Ilse Sienaert stepped down as director. NBB
- Capricorn Partners NV stepped down as director. NBB
- Esbee BV stepped down as director. NBB
- VIVES Partners SRL became a director. NBB
In short
From € 2.6 million loss in 2023 to € 238,871 loss in 2026.
A new publication or filing at ViroVet? We notify you, reason included.
Follow ViroVetDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Capricorn SCF NV (19.5%), Agri Investment Fund BV (19.5%), Biotech Fonds Vlaanderen NV (16.1%), AVF FPCI (12.5%), VIVES II - Louvain Technology Fund NV (9.8%) and Gemma Frisius - Fonds K.U. Leuven NV (8.1%).
Directors
According to the 2026 annual accounts
Patrik Haesen
Director
since 2021 · until 2026
Director · represented by Thomas Beke
Also active at: ETHERNA IMMUNOTHERAPIES, Flamingo Therapeutics
since 2020 · until 2026
Director · represented by Yannick Vancoppenolle
Also active at: NOVADIP BIOSCIENCES, TESSARES, AXINESIS, Sunrise, The Akkermansia Company, VOCSens, Vives Inter-University Fund, NeGIO Therapeutics +4 more
since 2024 · until 2026
since 2020 · until 2026
Director · represented by Ludwig Goris
Also active at: TS FLANDERS, CAPRICORN ICT ARKIV, Sensolus, REIN4CED, Confo Therapeutics, Minze, STORY CHIEF, Azumuta +22 more
since 2020 · until 2026
Managing director · represented by Erwin Blomsma
since 2020 · until 2026
Shareholders
19.5%
19.5%
AVF FPCI
12.5%
Elanco US Inc.
3.7%
Erwin Blomsma
1%
0.7%
Nesya Goris
0.4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Ambachtenlaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
WIX_COM, IL
Domain
Domain
virovet.com
Registered
2014-10-24
Registrar
Register.com - Network Solutions, LLC
Expires
2026-10-24
Website info
Features
Security
Network
Details
- Company number
- 0634.891.328
- VAT number
- BE 0634.891.328
- Registered office
- Ambachtenlaan 1, 3001 Leuven
- Names & denominations
- ViroVet
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 August 2015
- Peppol
- Active · Active since 15 Oct 2025
- Contact
- virovet.com [email protected] 016/29.97.26
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied